For the year ending 2025-12-31, TXG made $642,823K in revenue. -$43,544K in net income. Net profit margin of -6.77%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 642,823 | |||
| Cost of products and services revenue | 198,942 | |||
| Gross profit | 443,881 | |||
| Research and development | 238,632 | |||
| Selling, general and administrative | 316,134 | |||
| Gain on settlement | 49,900 | |||
| In-process research and development | 0 | |||
| Total operating expenses | 504,866 | |||
| Loss from operations | -60,985 | |||
| Interest income | 20,048 | |||
| Interest expense | 0 | |||
| Other income (expense), net | 1,030 | |||
| Total other income | 21,078 | |||
| Loss before provision for income taxes | -39,907 | |||
| Provision for income taxes | 3,637 | |||
| Net loss | -43,544 | |||
| Net loss per share, basic (in dollars per share) | -0.35 | |||
| Net loss per share, diluted (in dollars per share) | -0.35 | |||
| Weighted-average shares used to compute net loss per share, basic (in shares) | 124,749,885 | |||
| Weighted-average shares used to compute net loss per share, diluted (in shares) | 124,749,885 | |||
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)